CN106924740A - A kind of pharmaceutical composition for treating ALI - Google Patents
A kind of pharmaceutical composition for treating ALI Download PDFInfo
- Publication number
- CN106924740A CN106924740A CN201710153836.9A CN201710153836A CN106924740A CN 106924740 A CN106924740 A CN 106924740A CN 201710153836 A CN201710153836 A CN 201710153836A CN 106924740 A CN106924740 A CN 106924740A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- parts
- ali
- treating
- puerarin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims abstract description 13
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960001722 verapamil Drugs 0.000 claims abstract description 12
- 244000132619 red sage Species 0.000 claims abstract description 11
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims abstract description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- YSIHYROEMJSOAS-UHFFFAOYSA-N 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-n-[1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl]acetamide Chemical compound N=1N=C(C(C)(C)C)OC=1C(=O)C(C(C)C)NC(=O)CN(C(C(N)=CN=1)=O)C=1C1=CC=CC=C1 YSIHYROEMJSOAS-UHFFFAOYSA-N 0.000 claims description 5
- 244000046146 Pueraria lobata Species 0.000 claims description 5
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 5
- 240000007164 Salvia officinalis Species 0.000 claims description 5
- DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical group [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 235000005412 red sage Nutrition 0.000 claims description 5
- 238000000638 solvent extraction Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 229960000881 verapamil hydrochloride Drugs 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 210000004072 lung Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 4
- 230000008595 infiltration Effects 0.000 abstract description 3
- 238000001764 infiltration Methods 0.000 abstract description 3
- 206010030113 Oedema Diseases 0.000 abstract description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 238000012423 maintenance Methods 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 238000006213 oxygenation reaction Methods 0.000 abstract description 2
- 150000003254 radicals Chemical class 0.000 abstract description 2
- 230000004202 respiratory function Effects 0.000 abstract description 2
- 230000000630 rising effect Effects 0.000 abstract description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000035565 breathing frequency Effects 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition for treating ALI of biological pharmacy technical field, the main component of the pharmaceutical composition of the treatment ALI includes：Puerarin：20 25 parts；Verapamil：0.2 0.4 parts；UTI：12 parts；NE inhibitor：0.6 0.8 parts；Danshen：0.3 0.6 parts；Glutamine：0.4 0.8 parts.The invention proposes a kind of pharmaceutical composition for treating ALI; used cooperatively using Puerarin and Verapamil; ALI can effectively be treated; the rising of Plasma TNF alpha content can be suppressed; mitigate PMN infiltrations, eliminate free radical, mitigate lung tissue oedema degree; the effect of being effectively protected is served to ALI; and enable to arterial partial pressure of oxygen oxygenation index to significantly improve; improve the respiratory function of patient; the invention can not only effectively treat ALI and can also play maintenance action to lung; it is easy to use, it is with low cost.
Description
Technical field
The present invention relates to biological pharmacy technical field, specially a kind of pharmaceutical composition for treating ALI.
Background technology
ALI (Acute lung injury, ALI) be by many reasons cause with diffusivity lung cellular damage
Based on, there is the pathological change of characteristic in lung tissue structure, pulmonary edema and micro- not the opening of lung are pathological characters, and gas is influenceed rapidly
Function of exchange is that clinical characters lung inflammation and permeability increase syndrome.Its pathological characteristic is alveolar capillary endothelial cell
Damaged with alveolar epithelial cells, show as extensive pulmonary edema and microatelectasis.Pathophysiological change is mainly QS pulmonary shunt increasing
Plus decline with lung compliance.Clinical signs are that hypoxemia, breathing frequency speed and x-ray rabat double lung diffusivity infiltrations occur.
The cause of disease of ALI is complicated, and the death rate is high, severe infections, shock, wound, smoking, toxic poisoning, radiation
Beta radiation, hyperoxia etc. can cause ALI, but its pathomechanism not yet to illustrate completely.ALI is controlled at present
Treat main using heavy dose of Hormone stosstherapy, but lack convictive experimental evidence, substantial amounts of clinical research is it has proven convenient that sugar
Cortin can neither prevent the generation of ALI, to early stage ALI also without therapeutic action.Current treatment
The medication effect of ALI is bad, there is a problem that curing the symptoms, not the disease, it is impossible to fundamentally treats acute lung and damages
Wound, and treatment time is long, therefore, a kind of it is proposed that pharmaceutical composition for treating ALI.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for treating ALI, to solve above-mentioned background technology
The medication effect of the current treatment ALI of middle proposition is bad, there is a problem that curing the symptoms, not the disease, it is impossible to from
Fundamentally treat ALI, and the problem that treatment time is long.
To achieve the above object, the present invention provides following technical scheme：A kind of pharmaceutical composition for treating ALI,
The main component of the pharmaceutical composition of the treatment ALI includes：
Puerarin：20-25 parts；
Verapamil：0.2-0.4 parts；
UTI：1-2 parts；
NE inhibitor：0.6-0.8 parts；
Danshen：0.3-0.6 parts；
Glutamine：0.4-0.8 parts.
Preferably, it is raw material that the Puerarin uses the root of kudzu vine, is solvent extraction with n-butanol, and concentrated extracting solution reclaims positive fourth
Alcohol obtains paste, and paste crystallization is obtained.
Preferably, the Verapamil is verapamil hydrochloride, and its molecular weight is 491.07.
Preferably, the UTI is white or slightly yellow lyophilized block or powder, and it is by 143 amino acid groups
Into relative molecular mass is 67000.
Preferably, one or more during the NE inhibitor is for ONO-6818, EPI-HNE-4 or Sc-39026 combination and
Into.
Preferably, the Danshen is mixed using the red sage root and deionized water, is passed sequentially through decoction, filtering and is collected
Filtrate is obtained.
Preferably, the glutamine is white crystals or crystalline substance powder.
Compared with prior art, the beneficial effects of the invention are as follows：The invention proposes a kind of medicine for treating ALI
Compositions, are used cooperatively using Puerarin and Verapamil, can effectively treat ALI, can suppress blood plasma
The rising of TNF-α content, mitigates PMN infiltrations, eliminates free radical, mitigates lung tissue oedema degree, and ALI is served
Effect is effectively protected, and enables to arterial partial pressure of oxygen oxygenation index to significantly improve, improve the respiratory function of patient, should
Invention can not only effectively treat ALI and maintenance action can also be played to lung, easy to use, with low cost.
Specific embodiment
The technical scheme in the embodiment of the present invention will be clearly and completely described below, it is clear that described implementation
Example is only a part of embodiment of the invention, rather than whole embodiments.Based on the embodiment in the present invention, this area is common
The every other embodiment that technical staff is obtained under the premise of creative work is not made, belongs to the model of present invention protection
Enclose.
Embodiment 1
A kind of pharmaceutical composition for treating ALI, the main component of the pharmaceutical composition of the treatment ALI
Including：
Puerarin：20 parts, it is raw material that the Puerarin uses the root of kudzu vine, is solvent extraction with n-butanol, and concentrated extracting solution is returned
Receive n-butanol and obtain paste, paste crystallization is obtained；
Verapamil：0.3 part, the Verapamil is verapamil hydrochloride, and its molecular weight is 491.07；
UTI：1 part, the UTI is white or slightly yellow lyophilized block or powder, and it is by 143 amino
Acid composition, relative molecular mass is 67000；
NE inhibitor：0.8 part, the NE inhibitor is the one kind or many in ONO-6818, EPI-HNE-4 or Sc-39026
Plant and combine；
Danshen：0.5 part, the Danshen is mixed using the red sage root and deionized water, is passed sequentially through pan-fried
Filtrate is boiled, filters and collects to be obtained；
Glutamine：0.6 part, the glutamine is white crystals or crystalline substance powder.
Embodiment 2
A kind of pharmaceutical composition for treating ALI, the main component of the pharmaceutical composition of the treatment ALI
Including：
Puerarin：24 parts, it is raw material that the Puerarin uses the root of kudzu vine, is solvent extraction with n-butanol, and concentrated extracting solution is returned
Receive n-butanol and obtain paste, paste crystallization is obtained；
Verapamil：0.4 part, the Verapamil is verapamil hydrochloride, and its molecular weight is 491.07；
UTI：1.5 parts, the UTI is white or slightly yellow lyophilized block or powder, and it is by 143 ammonia
Base acid composition, relative molecular mass is 67000；
NE inhibitor：0.8 part, the NE inhibitor is the one kind or many in ONO-6818, EPI-HNE-4 or Sc-39026
Plant and combine；
Danshen：0.3 part, the Danshen is mixed using the red sage root and deionized water, is passed sequentially through pan-fried
Filtrate is boiled, filters and collects to be obtained；
Glutamine：0.8 part, the glutamine is white crystals or crystalline substance powder.
Embodiment 3
A kind of pharmaceutical composition for treating ALI, the main component of the pharmaceutical composition of the treatment ALI
Including：
Puerarin：23 parts, it is raw material that the Puerarin uses the root of kudzu vine, is solvent extraction with n-butanol, and concentrated extracting solution is returned
Receive n-butanol and obtain paste, paste crystallization is obtained；
Verapamil：0.3 part, the Verapamil is verapamil hydrochloride, and its molecular weight is 491.07；
UTI：1.5 parts, the UTI is white or slightly yellow lyophilized block or powder, and it is by 143 ammonia
Base acid composition, relative molecular mass is 67000；
NE inhibitor：0.7 part, the NE inhibitor is the one kind or many in ONO-6818, EPI-HNE-4 or Sc-39026
Plant and combine；
Danshen：0.4 part, the Danshen is mixed using the red sage root and deionized water, is passed sequentially through pan-fried
Filtrate is boiled, filters and collects to be obtained；
Glutamine：0.6 part, the glutamine is white crystals or crystalline substance powder.
Although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
Understanding can carry out various changes, modification, replacement to these embodiments without departing from the principles and spirit of the present invention
And modification, the scope of the present invention be defined by the appended.
Claims (7)
1. a kind of pharmaceutical composition for treating ALI, it is characterised in that：The pharmaceutical composition of the treatment ALI
Main component include：
Puerarin：20-25 parts；
Verapamil：0.2-0.4 parts；
UTI：1-2 parts；
NE inhibitor：0.6-0.8 parts；
Danshen：0.3-0.6 parts；
Glutamine：0.4-0.8 parts.
2. a kind of pharmaceutical composition for treating ALI according to claim 1, it is characterised in that：The Puerarin
It is raw material to use the root of kudzu vine, is solvent extraction with n-butanol, and concentrated extracting solution reclaims n-butanol and obtains paste, and paste crystallization is made
.
3. a kind of pharmaceutical composition for treating ALI according to claim 1, it is characterised in that：The Wella handkerchief
Rice is verapamil hydrochloride, and its molecular weight is 491.07.
4. a kind of pharmaceutical composition for treating ALI according to claim 1, it is characterised in that：The Wu Sita
Fourth is white or slightly yellow lyophilized block or powder, and it is made up of 143 amino acid, and relative molecular mass is 67000.
5. a kind of pharmaceutical composition for treating ALI according to claim 1, it is characterised in that：The NE suppresses
Agent is combined for one or more in ONO-6818, EPI-HNE-4 or Sc-39026.
6. a kind of pharmaceutical composition for treating ALI according to claim 1, it is characterised in that：The Salvia miltiorrhiza Bge water
Extract is mixed using the red sage root and deionized water, is passed sequentially through decoction, filtering and collection filtrate and is obtained.
7. a kind of pharmaceutical composition for treating ALI according to claim 1, it is characterised in that：The glutamy
Amine is white crystals or crystalline substance powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710153836.9A CN106924740A (en) | 2017-03-15 | 2017-03-15 | A kind of pharmaceutical composition for treating ALI |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710153836.9A CN106924740A (en) | 2017-03-15 | 2017-03-15 | A kind of pharmaceutical composition for treating ALI |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106924740A true CN106924740A (en) | 2017-07-07 |
Family
ID=59433798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710153836.9A Pending CN106924740A (en) | 2017-03-15 | 2017-03-15 | A kind of pharmaceutical composition for treating ALI |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106924740A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111329999A (en) * | 2020-03-27 | 2020-06-26 | 广东天普生化医药股份有限公司 | Application of ulinastatin in preparing medicine for treating novel coronavirus pneumonia |
| WO2022165031A1 (en) * | 2021-01-29 | 2022-08-04 | DiaMedica USA Inc. | Ulinastatin polypeptides for treating diseases |
| US11725043B2 (en) | 2020-03-05 | 2023-08-15 | DiaMedica USA Inc. | Ulinastatin polypeptides |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1449823A (en) * | 2003-05-26 | 2003-10-22 | 广东天普生化医药股份有限公司 | Use of ulinastatin in treating SARS and medicinal composition thereof |
| CN101394860A (en) * | 2006-01-13 | 2009-03-25 | 范斯坦医药研究院 | Inhibition of inflammatory cytokine production with tanshinones |
| CN102961380A (en) * | 2012-11-16 | 2013-03-13 | 济南环肽医药科技有限公司 | Pharmaceutical composition for treating acute lung injury |
| JP2018131429A (en) * | 2017-02-14 | 2018-08-23 | 拓己 佐藤 | Use of organic acid as method to enhance effect of nrf2 activator |
-
2017
- 2017-03-15 CN CN201710153836.9A patent/CN106924740A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1449823A (en) * | 2003-05-26 | 2003-10-22 | 广东天普生化医药股份有限公司 | Use of ulinastatin in treating SARS and medicinal composition thereof |
| CN101394860A (en) * | 2006-01-13 | 2009-03-25 | 范斯坦医药研究院 | Inhibition of inflammatory cytokine production with tanshinones |
| CN102961380A (en) * | 2012-11-16 | 2013-03-13 | 济南环肽医药科技有限公司 | Pharmaceutical composition for treating acute lung injury |
| JP2018131429A (en) * | 2017-02-14 | 2018-08-23 | 拓己 佐藤 | Use of organic acid as method to enhance effect of nrf2 activator |
Non-Patent Citations (1)
| Title |
|---|
| 王正冠等: "治疗急性肺损伤药物非临床研究进展", 《临床检验杂志(电子版)》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11725043B2 (en) | 2020-03-05 | 2023-08-15 | DiaMedica USA Inc. | Ulinastatin polypeptides |
| CN111329999A (en) * | 2020-03-27 | 2020-06-26 | 广东天普生化医药股份有限公司 | Application of ulinastatin in preparing medicine for treating novel coronavirus pneumonia |
| WO2022165031A1 (en) * | 2021-01-29 | 2022-08-04 | DiaMedica USA Inc. | Ulinastatin polypeptides for treating diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101543467B (en) | Aloe gel and preparation method thereof | |
| CN106924740A (en) | A kind of pharmaceutical composition for treating ALI | |
| CN110538189A (en) | Eucommia ulmoides extract composition for treating renal fibrosis and application thereof | |
| CN110742908A (en) | Preparation process of periplaneta americana extract | |
| CN105617356A (en) | Medicine for treating asthma | |
| CN1151807C (en) | Chinese-medicinal spray for treating chronic pharyngolaryngitis and its preparing process | |
| CN107485675A (en) | A kind of wound Regeneration and Repair removing necrosis, promoting granulation powder and preparation method and application method | |
| CN107233257A (en) | A kind of Chinese toon glue anti-acne facial cleanser | |
| CN108685964B (en) | Application of gerbera piloselloides extract and preparation method of active ingredients of gerbera piloselloides extract | |
| CN102038776A (en) | Oral liquid capable of relieving cough and asthma and preparation method thereof | |
| CN109369398B (en) | Process for purifying chlorogenic acid in corn vinasse | |
| RU2416431C1 (en) | Method of treating respiratory diseases in calves | |
| CN1785221B (en) | Powder injection containing radix bupleuri and its preparation method | |
| CN108236623B (en) | Pharmaceutical composition, traditional Chinese medicine oral liquid, traditional Chinese medicine granules and preparation method and application thereof | |
| CN108324829A (en) | A kind of Hemorrhagic shock mixture and preparation method thereof containing ginseng | |
| RU2040267C1 (en) | Method for curing maxillary sinusitis | |
| CN114053390B (en) | Traditional Chinese medicine composition with hypoxia tolerance and preparation method and application thereof | |
| CN102309522B (en) | Deproteinised porcine blood extract oral paste and preparation technology thereof | |
| CN1628649A (en) | Pharmaceutical combination containing red sage root element and preparation method thereof | |
| CN116211908A (en) | Traditional Chinese medicine composition for treating internal hemorrhage and preparation method thereof | |
| CN1732912A (en) | Freeze dry tiopronin preparation without adjuvant for intravenous injection and its preparation process | |
| CN113827542A (en) | Anti-aging facial mask | |
| CN115282184A (en) | External ointment for treating tinea | |
| CN115429788A (en) | Medicine for treating demyelinating diseases and application thereof | |
| CN104815320A (en) | Anti-dust nasal cavity cleaning agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170707 |